All currently approved combinations are hallmarked by the development of drug resistance, with 5‐year progression‐free survival estimated at less than 20%, leaving many patients with dual BRAF inhibitor (BRAFi) and MEK inhibitor (MEKi) resistant tumours and limited therapeutic options. The gene discussed is BRAF; the disease is neoplasm.